Abstracts tagged "interleukins (IL)"

Abstract Number: 1816 • 2014 ACR/ARHP Annual Meeting
Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice
Tom Ederveen¹, Rebecca Rogier², Jos Boekhorst¹, Harm Wopereis³, Johan Garssen³, Sacha van Hijum¹, Fons A.J. van de Loo², Marije I. Koenders², Wim B. van den Berg² and Shahla Abdollahi-Roodsaz⁴, ¹Centre for Molecular Bioinformatics Nijmegen (CMBI), Radboud university medical center, Nijmegen, Netherlands, ²Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Danone Research, Wageningen, Netherlands, ⁴Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose Interleukin-1 (IL-1) plays a pivotal role in inflammation and autoimmunity. Mice deficient in the IL-1 receptor antagonist (IL-1Ra-/-) spontaneously develop a T cell-driven autoimmune…
Abstract Number: 1746 • 2014 ACR/ARHP Annual Meeting
Involvement of IL-17-Producing MAIT Cells in the Pathogenesis of Rheumatoid Arthritis
Eri Hayashi¹, Asako Chiba², Mie Kitagaichi³, Kurisu Tada³, Ken Yamaji⁴, Naoto Tamura¹, Yoshinari Takasaki³ and Sachiko Miyake², ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are a subset of innate-like lymphocytes which are restricted by the MHC-related molecule-1 (MR1) and express a semi-invariant TCRα…
Abstract Number: 1732 • 2014 ACR/ARHP Annual Meeting
Attenuation of Sclerodermatous Graft Versus Host Disease (sclGVHD) in IL4RA Receptor-Deficient Mice
Katia Urso¹, Kelly Tsang², Robert Lafyatis³ and Antonios O. Aliprantis², ¹Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose Scleroderma is a rare autoimmune disease characterized by the accumulation of fibrotic tissue in multiple organs including the skin, gut and lungs. To date,…
Abstract Number: 1511 • 2014 ACR/ARHP Annual Meeting
COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Wibke Lembke, Bernd Schlereth, Julian Bertschinger, Dragan Grabulovski and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologic therapeutics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, there is still…
Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Dragan Grabulovski, Michela Silacci, Wibke Lembke, Wenjuan Zha, Richard Woods, Roger Santimaria, Julian Bertschinger and Mathias Locher, Covagen AG, Schlieren, Switzerland
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…
Abstract Number: 1492 • 2014 ACR/ARHP Annual Meeting
Safety and Tolerability of NNC01140006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis
Frank Wagner¹, Birte Skrumsager² and Sergey Fitilev³, ¹Charité Research Org GmbH, Berlin, Germany, ²Novo Nordisk A/S, Søborg, Denmark, ³Department of Clinical Pharmacology, Municipal Clinic #2, Moscow, Russia
Background/Purpose A phase 1, randomised, double-blind, placebo-controlled, dose-escalation trial was conducted to assess the safety and tolerability of the anti-IL-21-antibody NNC0114-0006, in patients with active…
Abstract Number: 1459 • 2014 ACR/ARHP Annual Meeting
IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT3
Junqing Zhu¹, Juan Li¹ and Xiaoguang Chen², ¹Nanfang Hospital, College of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, ²School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, China
Background/Purpose: Although CD3-CD56+NKp44+ natural Killer cells (NKp44+NK cells) have been linked to autoimmune diseases including inflammatory bowel disease, ankylosing spondylitis, and primary Sjogren's syndrome, the…
Abstract Number: 1253 • 2014 ACR/ARHP Annual Meeting
Anakinra – a Promising New Therapy for Idiopathic Recurrent Pericarditis
Sonia Jain¹, Charat Thongprayoon², Raul Espinosa¹, Sharonne Hayes¹, Kyle Klarich¹, Kevin Moder³, Nandan Anavekar¹, Jae Oh¹ and Eric L. Matteson⁴, ¹Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks…
Abstract Number: 1030 • 2014 ACR/ARHP Annual Meeting
ABT-122, a Novel Dual Variable Domain (DVD)-Ig^TM, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects
Melanie Ruzek¹, Donna Conlon¹, Heikki Mansikka², Robert Padley² and Carolyn Cuff³, ¹AbbVie, Inc, Worcester, MA, ²AbbVie, Inc, North Chicago, IL, ³Immunology, AbbVie, Inc, Worcester, MA
Background/Purpose: TNF and IL-17 contribute to the pathogenesis of several inflammatory disorders and are known to synergistically induce chemokines and cytokines, including chemokine (C-X-C motif)…
Abstract Number: 998 • 2014 ACR/ARHP Annual Meeting
β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10
Georg Pongratz¹, Clemens Wiest², Madlen Melzer² and Rainer Straub³, ¹Internal Medicine I, University Hospital Regensburg, Regensburg, Germany, ²University Hospital Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose Splenic B cells from collagen-induced arthritis (CIA) mice react to a β2-adrenoceptor (AR) stimulus with increased IL-10 production and adoptive transfer of these cells…
Abstract Number: 951 • 2014 ACR/ARHP Annual Meeting
Safety, Tolerability, and Functional Activity of ABT-122, a Dual TNF- and IL-17A–Targeted DVD-Ig™, Following Single-Dose Administration in Healthy Subjects
Heikki Mansikka¹, Melanie Ruzek², Margaret Hugunin², Alexander Ivanov², Alyssa Brito², Anca Clabbers², Carolyn Cuff³, Chung-Ming Hsieh², Martin Okun¹, Renee Heuser¹, David Carter¹, Barbara Hendrickson¹, Dipak Pisal¹, Sandra Goss¹, Jia Liu¹, Charles Locke¹, Nasser Khan¹ and Robert Padley¹, ¹AbbVie, Inc, North Chicago, IL, ²AbbVie, Inc, Worcester, MA, ³Immunology, AbbVie, Inc, Worcester, MA
Background/Purpose: Several lines of evidence indicate that greater clinical efficacy and protection of joints may be possible in patients with RA by neutralizing TNF and…
Abstract Number: 1856 • 2013 ACR/ARHP Annual Meeting
Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Christine Huppertz¹, Marija Curcic Djuric¹, Robert Hennze¹, Friedrich Raulf¹, Frank Kolbinger¹, Anis Mir¹ and David Lee², ¹Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The pro-inflammatory cytokine interleukin-17A (IL-17A) activates fibroblast-like synoviocytes (FLS) and other mesenchymal cells via the IL-17RA/RC receptor. FLS are a major source of inflammatory…
Abstract Number: 1653 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Synovial IL-21+CD4+ T Cells Specifically Induce Matrix Metalloproteinase Production By Fibroblast-Like Synoviocytes
Maria C. Lebre¹, Pedro L. Vieira², Saïda Aarrass¹, Thomas Newsom-Davis², Paul Peter Tak³ and Gavin R. Screaton², ¹Clinical Immunology and Rheumatology & Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Immunology, Imperial College London, London, United Kingdom, ³Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: IL-21 is a cytokine produced by activated CD4+ T cells and T follicular helper cells (TFh) that has been implicated in several autoimmune diseases…
Abstract Number: 1440 • 2013 ACR/ARHP Annual Meeting
Effects Of Tocilizumab On Serum Cytokines In Rheumatoid Arthritis With An Inadequate Response To Disease-Modifying Antirheumatic Drugs
Sang Jin Lee^1,2, Kyung Rok Kim³, Sang Hyun Joo³, Jae Myung Lee³, In Ah Choi³, Joo Youn Lee², Hyun Jung Yoo², Eun Young Lee⁴, Eun Bong Lee¹, Won Park⁵, Sung Hwan Park⁶, Seung-Cheol Shim⁷, Dae-Hyun Yoo⁸, Han Joo Baek⁹, Hyun Ah Kim¹⁰, Soo Kon Lee¹¹, Yun Jong Lee¹, Young Eun Park¹², Hoon-Suk Cha¹³ and Yeong Wook Song^2,3, ¹Division of Rheumatology, Department of Internal Medicine, Rheumatology, Seoul National University, Seoul, South Korea, ²Department of molecular medicine and biophamaceutical sciences,Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁴Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Rheumatology, The Catholic University, Seoul, South Korea, ⁷Medicine, Rheumatology, Eulji University, Daejeon, South Korea, ⁸Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Rheumatology, Rheumatology, Gachon University, Incheon, South Korea, ¹⁰Division of Rheumatology, Department of Internal Medicine, Hallym university, Kyunggi, South Korea, ¹¹Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ¹²Rheumatology, Rheumatology, Pusan Nationl University, Pusan, South Korea, ¹³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: The objective of this study was to investigate the effects of tocilizumab on serum cytokines in rheumatoid arthritis (RA) patients with an inadequate response…
Abstract Number: 1375 • 2013 ACR/ARHP Annual Meeting
Synergistic Enhancement Of Aggregated IgG-Induced Tumor Necrosis Factor α In Human Synovial Mast Cells By Interleukin 33
Hyunho Lee^1,2, Jun-ichi Kashiwakura³, Masahiko Yanagisawa^1,2, Yuki Okamura^1,2, Takao Ishii², Masayuki Seki², Shu Saito², Yasuaki Tokuhashi², Chisei Ra¹ and Yoshimichi Okayama¹, ¹Allergy and Immunology Group, Nihon University School of Medicine, Tokyo, Japan, ²Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan, ³Laboratory for Allergic Disease, RIKEN Center for Integrateive Medical Sciences, Kanagawa, Japan
Background/Purpose: Recent studies suggest that human synovial mast cells (MCs) are involved in the pathogenesis of rheumatoid arthritis (RA). Circulating IgG isotype autoantibodies and synovial…

« Previous Page
1
…
6
7
8
9
10
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.